Title: A semi-quantitative analysis of pathological 68Ga-DOTATATE PET/CT uptake by primary site dependent neuroendocrine tumor metastases
Abstract: 1929 Objectives The aim of this study was to localize sites of metastases of neuroendocrine tumors (NET). Sites of metastasis were described in relation to primary NET orgin. Further characterization was made using semiquantitative analysis - standardized uptake value (SUVmax) which correlated with pathological 68Ga-DOTATATE uptake. Methods 245 patients; 89 men and 156 women with a mean age of 56.1±12.8, were imaged 60-70 minutes post 120-200 MBq (3.2-5.4 m Ci) 68Ga-DOTATATE injection, using a Siemens Medical Solutions Biograph 64 PET/CT Truepoint. Visual assessments were made, using a multimodality workstation, and sites of increased uptake were recorded. Pathological 68Ga-DOTATATE uptake was quantified using semiquantitative analysis (SUVmax). Results Primary tumors sites were localized to the intestine, pancreas and lungs. Metastases, with respect to the primary sites, were predominantly the liver (49% vs 33% vs 40%), lymph nodes (34% vs 24% vs 25%), and bone (20% vs 10% vs 30%). SUVmax (mean ± SD) was highest in the liver (28.7±23.5), followed by the adrenal glands (24.7±9.7), bone (24.1±36.8), intestine (21.9±21.9), lymph nodes (22.5±24.5), pancreas (24.9±28.1), peritoneum (21.9±24), stomach (14±5.6), thyroid (10.9±10.3), lung (10±9.3) and the brain (8.7 ±7). Conclusions 68Ga-DOTATATE PET/CT is a superior mode of imaging in terms of somatostatin receptor positive tumors; moreover, the detection of small lesions. In addition, it allows for visualizations of bone and lymph metastases which are not imaged by any other methods. The knowledge of SUVmax in 68Ga-DOTATATE PET/CT could potentially lend information on tumour cell receptor density; which would entail a significant bearing on the planning of target radionuclide therapy.
Publication Year: 2013
Publication Date: 2013-05-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot